

# We are an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.

## We enable healthier lives, everywhere, every day

As the leader in women's health, we deliver life-changing and life-saving diagnostic, detection and surgical products that are rooted in science, driven by technology, and inspired by our desire to empower women and help healthcare professionals diagnose and treat their patients with growing certainty, precision, and ever-greater peace of mind.

### Genius™ 3D™ exam

The Genius™ 3D Mammography™ exam<sup>1</sup> detects 20-65% more breast cancers compared to 2D mammography alone.<sup>2</sup>



### Brevera® Breast Biopsy System

The Brevera® breast biopsy system with CorLumina® imaging technology is the world's first solution to combine tissue acquisition, real-time imaging, verification and advanced post-biopsy handling—all in one, integrated system.



### Affirm® Prone Biopsy System

Superior biopsy imaging using Genius 3D technology. Improved workflow results in faster procedures and an enhanced patient experience.



### Horizon™ DXA Bone Densitometry

Provides high-quality clinical images that reveal the smallest fractures at the earliest stage—helping to keep patients strong and healthy. Horizon™ was designed to assess osteoporosis, obesity and aortic calcifications.



### NovaSure® for AUB

NovaSure endometrial ablation for abnormal uterine bleeding (AUB) can dramatically improve a woman's comfort, confidence and quality of life. It is a safe, simple solution used by more than 3 million women since 2001.



### MyoSure® Hysteroscopic Tissue Removal

The MyoSure procedure enables fast, safe removal of fibroids, polyps and retained products of conception in less than 15 minutes—without having to make a single incision. It enables convenient removal of intrauterine pathology under direct visualization.



### Panther® System

Offers best-in-class automation and workflow for molecular diagnostics, giving laboratories greater freedom and flexibility with true walk-away processing and random access sampling. Delivers a broad menu of the most sensitive, accurate, and precise assays.



### Aptima® Molecular Diagnostic Assays

Hologic developed the first FDA-cleared nucleic acid test for infectious diseases over 30 years ago. Today, our state-of-the-art Aptima assays quickly identify diseases like chlamydia, gonorrhea, trichomoniasis, HIV-1, HCV and HBV at early stages, often within days of infection.



### ThinPrep® Pap Test

Cervical cancer was the #1 cancer killer of women prior to the introduction of Pap screening, now it's #14.<sup>3</sup> Hologic's ThinPrep liquid-based cytology test has revolutionized cervical cancer screening and is the leading cervical specimen collection product in the world.



### LOCalizer™

The LOCalizer™ wire-free guidance system is designed to mark and guide the user to non-palpable breast lesions using a miniature radiofrequency identification (RFID) tag.



### FluorSCAN® InSight™ Mini C-arm Extremities Imaging System

Provides excellent image quality and system versatility for all extremity imaging needs. The system is designed to help minimize radiation by preventing patient and surgeon exposure to the unused area of the detector.



©2020 Hologic, Inc. U.S./International. All rights reserved. Printed in the United States. Hologic, 3D Mammography, Aptima, Dimensions, Genius, NovaSure, Selenia, The Science of Sure and ThinPrep are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is not intended as a product solicitation or promotion. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear.

1. The Genius™ exam is only available on the Hologic® 3D Mammography™ system. Please visit <https://www.MyGenius3D.com> for more information. 2. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507. 3. <https://www.report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76>

# Financial Results

## REVENUE HIGHLIGHTS 1Q20

NON-GAAP REVENUE (\$M)	1Q20	Reported Δ vs. 1Q19	CC Δ vs. 1Q19
Diagnostics <sup>1</sup>	\$311.5	5.0%	5.5%
Breast Health	\$331.1	2.0%	2.4%
Medical Aesthetics <sup>5</sup>	\$65.3	(18.2)%	(17.7)%
GYN Surgical	\$119.1	9.9%	10.2%
Skeletal Health	\$23.5	10.8%	11.4%
<b>Total Revenue</b>	<b>\$850.5</b>	<b>2.4%</b>	<b>2.8%</b>
Core Revenue <sup>4</sup>	\$773.2	5.0%	5.4%
Organic Revenue <sup>5</sup>	\$767.1	4.1%	4.6%
US	\$632.7	1.8%	1.8%
OUS	\$217.8	4.3%	6.0%

## FINANCIAL OVERVIEW 1Q20

NON-GAAP IN MILLIONS ex. EPS	1Q20	Δ vs. 1Q19
Revenue (\$M)	\$850.5	2.4%
Core Revenue <sup>4</sup>	\$773.2	5.0%
Organic Revenue <sup>5</sup>	\$767.1	4.1%
Gross Margin	61.6%	(60 bps)
Operating Expenses	\$289.3	5.3%
Operating Margin	27.5%	(170 bps)
Net Income	19.3%	40 bps
Diluted EPS	\$0.61	5.2%
EBITDA	\$261.9	0.5%

## 2020 FINANCIAL GUIDANCE<sup>2</sup>

NON-GAAP	'20 Guidance	Reported vs. '19	CC vs. 2Q19	CC Organic vs. 2Q19
Revenue (\$M)	\$3,238–\$3,268	(3.8%) to (2.9%)	(3.5%) to (2.6%)	4.0% to 5.0%
Diluted EPS	\$2.63–\$2.67	8.2% to 9.9%		

NON-GAAP	2Q20 Guidance	Reported vs. 2Q19	CC vs. 2Q19	CC Organic vs. 2Q19
Revenue (\$M)	\$770–\$780	(5.9%) to (4.7%)	(5.4%) to (4.2%)	3.4% to 4.8%
Diluted EPS	\$0.61–\$0.63	5.2% to 8.6%		

## CAPITAL DEPLOYMENT PRIORITIES

Expect adjusted free cash flow in the \$650-\$700 million range in FY20


Business development priorities

- Tuck-in acquisitions
  - Attractive to revenue, EPS growth rates
  - Attractive ROIC
  - Leveraging existing sales channels


Share repurchases

- \$131 million remaining on board authorization at the end of 1Q20


## NET DEBT & LEVERAGE RATIO<sup>3</sup>




## REVENUE & CC GROWTH RATES




## 2019 DIVISIONAL REVENUE BY GEOGRAPHY




## NON-GAAP EPS



## NON-GAAP NET MARGIN %



## ROIC



1. Includes contributions from divested blood screening business. Excluding blood, Diagnostics sales increased 6.1% on a reported basis, or 6.5% in constant currency.

2. Guidance provided by press release on 1/29/20. Presentation here is not, and should not be construed as, re-affirmation of guidance. Guidance assumes diluted shares outstanding of approximately 268 to 269 million for the full year and an annual effective tax rate of approximately 21.75%.

3. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA.

4. Core Revenue excludes divested Blood Screening and Cynosure Medical Aesthetics businesses.

5. Organic Revenue excludes the divested Blood Screening and Cynosure Medical Aesthetics businesses, as well as the acquired SSI business.

6. Divestiture of Medical Aesthetics business was completed on 12/30/19.